

**DM SEMINAR**  
**FEBRUARY 04, 2005**

**THORACOSCOPY (MEDICAL  
AND VIDEO ASSISTED  
SURGICAL)**

**NAVNEET SINGH**  
**DEPARTMENT OF PULMONARY  
MEDICINE**

# HEADINGS

- INTRODUCTION
- MEDICAL THORACOSCOPY VS VATS
- INDICATIONS
- CONTRA-INDICATIONS
- COMPLICATIONS
- PROCEDURE OVERVIEW
- FUTURE DIRECTIONS

# INTRODUCTION

- First introduced by Jacobaeus (internist, 1910, Stockholm) as diagnostic procedure in two cases
  - of exudative (tuberculous) pleuritis
- Accumulated experience of thoracoscopy with:
  - Malignant PE (differentiate between 1° & 2° tumours of chest wall, pleura, lung & mediastinum)
  - Tubercular PE
  - Rheumatic and nonspecific parapneumonic effusions
  - Empyemas (esp nontubercular)
  - Pneumothorax (visualizing defect in idiopathic spont


# INTRODUCTION

- Subsequent 4 decades → Thoracoscopy used worldwide almost exclusively for lysis of pl adhesions by thoracocautery ("Jacobaeus' Operation") – facilitate pneumothorax as Rx of TB
- Initiation of use for evaluation of pl-pul diseases  
Europe → MT came under scope of respiratory physicians
- Concurrent use of ST (VATS) by thoracic surgeons


# MT vs VATS

	MT	VATS
Main Indications	Dx of Pl disease	Rx
Anaesthesia	LA/ Sedation	GA
Intubation	No	Yes (Double lumen)
Procedure Site	Suite/Room	OT
Ports of entry	Single-Double	Multiple ( $\geq 3$ )
Instruments	Non-disposable	Disposable
Invasiveness	+	++
Safety	++	+
Cost	+	++

**DIAGNOSIS**



**TREATMENT**



WHEN TO DO?

# INDICATIONS

## *Pleural Effusion of Unknown Etiology*

- >20–25% of PE remain undiagnosed even after extensive diagnostic work-up of PF
- Dx by cytologic examination → Metastatic pleural involvement (60 to 80 % )
- Dx by closed needle Bx ~ 45% (neoplastic inv)
- If facilities exist, MT should be performed (high sensitivity for malignancy and TB) → ~ 4 % remain undiagnosed or truly idiopathic



# INDICATIONS

## *Pleural Effusion of Unknown Etiology*

- Initial Evaluation of PE nondiagnostic (esp if suspicion of neoplastic disease) → MT:
  - Exploration + parietal pleural Bx → Dx in 90–100%
  - Staging
  - Complete fluid removal → Re-expansion potential
- VATS ~ MT (more invasive & expensive, results similar) – reserved for cases where MT difficult or impossible e.g. severe pleuropulmonary adhesions (repeated therapeutic thoracenteses)

# INDICATIONS

## *Tubercular Pleural Effusion*

- Dx by closed needle Bx ~ 70% (30–90 %)
- Use of MT:
  - Visualization of grayish-white granuloma (parietal & diaphragmatic pl esp costovertebral gutter)
  - Multiple biopsies from selected sites (→HP Dx in 94–98 %)
  - TB cultures more frequently positive (esp when fibrin production is significant)
- Dx by MT + Culture + HPE → ~ 100% (> Closed needle Bx + Culture of PE)

# INDICATIONS

## *Tubercular Pleural Effusion*

- Areas with low prevalence of TB, MT should be done when needle Bx are -ve
- Areas with high prevalence, MT not usually reqd for Dx since most cases Dx by needle Bx (HPE + AFB stain & C/S from each of 3 specimens).

If Cytology & closed needle Bx both -ve,  
probability of Dx by MT ~ 5-6%

# INDICATIONS

## *Tubercular Pleural Effusion*

- Indications – when requirement for :
  - Lysis of adhesions
  - Large amounts of tissue both for Dx and testing for drug resistance and susceptibility
- ? Initial complete drainage of PE during MT
  - greater symptomatic improvement ~ any other Mx strategy (incl use of steroids)
- No studies to compare effect of MT (early Dx + complete drainage) + ATT with ATT alone.

# INDICATIONS

## *Mesothelioma*

- Dx by cytologic exam → < 20 % (4 -77 % )
- M.f. cause of false -ve cytology – Early MM
- Closed needle Bx – specimens small (size & no) → inadequate for all immunohistochemical stains & EM exam needed for definitive Dx
- Adv of MT:
  1. Specimens large & full-thickness from several areas (no req for open pl Bx by lat or mini thoracotomy) → Early Dx (accuracy by HPE upto 98 % ) + Better H/P classification +More

# INDICATIONS

## *Mesothelioma*

2. If intrapleural CT or surgical Rx not under consideration → Dx + Pleurodesis simultaneously
3. Benign asbestos-related PE (Dx of exclusion):
  - Fibrohyaline/calcified, thick, pearly white pl plaques
  - Pl ± pul Bx → demonstration of asbestos fibres
- Limitations:
  - Inadequate visualization (extensive adhesions)
  - Tumor growth through thoracoscopic incision sites Radiation to area surrounding the incision sites?
  - Inherent difficulties in pathologic identification →

# INDICATIONS

## *Recurrent Pleural Effusion of Benign Etiology*

- CCF, cardiac surgery, nephrotic syndrome, CT disorders
- Indicated for recurrent effusions causing symptoms & not controlled by repeated large-volume thoracentesis
- Pleural Bx → Exclude infectious or neoplastic etiologies → Pleurodesis

# INDICATIONS

## *Malignant Pleural Effusions*

- M. C. indication for MT (both Dx & Rx)
- Dx by PF Cytology → ~ 60%
- Dx by Closed needle Bx → ~ 45 %
- Dx by PF Cytology + Closed needle Bx → ~ 75 %
- Dx by MT alone → ~ 95 % (Lung Ca, Diffuse MM, Extrathoracic primaries)
- Dx by MT + PF Cytology → ~ 96 % (+ 1-2%)
- Dx by all combined → ~ 97% (+ 2-3%)



# INDICATIONS

## *Malignant Pleural Effusions*

- Staging (esp Bronchogenic Ca → Determine operability)
- Metastatic PE → Large size Bx (direct vision)  
→ Determination of site of primary
- Metastatic PE (breast cancer) → ER/PR status
- Lymphomas → Better diagnostic yield + morphological classification

# INDICATIONS

## *Malignant Pleural Effusions*

1. Removal of max qty of fluid with min risk of pul oedema (immediate equilibration of pressures by direct entrance of air into pl cavity)
2. Re-expansion potential of lung evaluated by visual inspection
3. Breaking up/removal of loculations & adhesions
4. Pleurodesis – chemical or by pleurectomy using standard dissection techniques or hydrodissection

# INDICATIONS

## *Chylothorax*

- M. C. cause – Trauma or malignancy (lymphoma)
- Exploration (MT/VATS) can precede/replace open thoracotomy
- If torn thoracic duct visualized (PO heavy cream 1 hr prior to procedure)  
→ Clipped/ligated
- Anticipated Survival Time short (esp lymphoma) → Pleurodesis → Resolution of PE + prevention of Nutritional & Immunologic deterioration

# INDICATIONS

## *Empyema*

- Debridement of fibrinous adhesions + evacuation of loculated fluid/debris → ↓ duration of hospital stay + avoidance of open thoracotomy
- Timing of thoracoscopic intervention critical (? 3–5 d after ICTD ineffective)
- VATS → Success rate of >80 %  
*Cassina PC et al. J Thorac Cardiovasc Surg 1999; 117:234–238*
- ? Thoracoscopy vs STK use vs OT + Decortication

# INDICATIONS

## *Pulmonary Diseases*

- Indications for thoracoscopy:
  1. Evaluation of single/multiple peripheral pulmonary opacities where TBLB/Percutaneous LB non-Dx
  2. DPLD with peripheral involvement (after simpler techniques unsuccessful) eg lymphangitis etc
  3. Bx of visceral pl + lung surface in pts with proven or suspected pl malignancy (mets/MM) for staging
- Sens + Invasiveness → OLB > MT/VATS > TBLB

# INDICATIONS

## *Pulmonary Diseases*

- Adv over TBLB:
  1. Larger Bx size
  2. Ability to choose Bx site (direct visualization)
  3. Bleeding can be Mx with electrocoagulation/laser.  
Bx can be taken using endoscopic stapling device.
- Sensitivity – overall  $\geq 90\%$  :
  1. Sarcoidosis stage II/III  $\rightarrow \sim 98\%$
  2. Diffuse malignant lung diseases  $\rightarrow \sim 90\%$
  3. Fibrotic lung disease  $\rightarrow \sim 85\%$

# INDICATIONS

## *Pulmonary Diseases*

- Dis adv – Parietal/visceral pl seeding of tumor cells after thoracoscopic removal of lung nodules/masses.
- Morbidity rates minimal even in pts who are elderly, have poor lung function or reduced performance status. Postop/post-procedure stay in ICU rarely reqd. Usually pts D/S in < 3 days

# INDICATIONS

## *Spontaneous Pneumothorax*

- Pts with recurrent/prolonged (> 5 d) pneumoTx MT/VATS better ~ repeated ICTD
- Thoracoscopic findings in PSP :
  - Type I ('Normal appearance')
  - Type II (Pl-Pul adhesions)
  - Type III (Small blebs or bullae < 2 cm)
  - Type IV (Large bullae > 2 cm)
- Airleaks localized by saline bathing of collapsed lung + Use of PPV



# INDICATIONS

## *Spontaneous Pneumothorax*

- Blebs/bullae – ligated/removed by APC, electrocautery, Nd:YAG laser or stapling device
- Wedge resection of blebs/bulla ↓ LA described
- Results ~ OT → Trade off b/w higher recurrence (5–10% vs 1–3%) AND lower morbidity. Can precede/replace OT
- Improved visualization techniques → **No Such Thing as Endoscopically Normal Lung (Type I)** – Minor blebs (± small bullae) 1–2 mm – Too small for detection by CT or resection

# INDICATIONS

## *Spontaneous Pneumothorax*

- COPD + SSP :
  - Prospectively study of thoracoscopic talc pleurodesis
  - 41 pts with COPD and SSP
  - Mean FEV1 41 % predicted
  - Maj of SPs 20-50 % in size - 1/3 recurrent
  - Success rate of 95 % after median F/U of 3 yrs
  - Mortality rare of 10 % within 30 d of procedure
  - 'Can be performed with acceptable mortality in patients with advanced COPD'

*Lee et al, Chest 2004; 125: 1315-*

# INDICATIONS

## *Bullectomy/LVRS*

- Endoscopic loop ligation + stapling > Endoscopic laser resection (Nd:YAG)
- B/L procedures > U/L procedures
- Results/morbidity/mortality ~ OT but costs < OT

*NETT Research Group N Engl J Med 2003; 348: 2059-2073*

- Short term:  $\uparrow$  Pul  $f_x$  exercise performance & QOL
- Long term: FEV1  $\downarrow$  ( $\approx$  preresection values within 2 yrs)

# INDICATIONS

## *Chest Trauma*

- Evaluation/ Mx in blunt/penetrating trauma:
  1. Diaphragmatic injury
  2. Chest wall bleeding
  3. Traumatic pneumoTx /chyloTx/hemoTx
  4. Lung parenchymal lacerations
  5. Trapped lung (after prolonged HemoTx) → Removal of fibrous peel + loculations/adhesions → lung re-expansion → pleurodesis
- Difficulty (active bleeding/suboptimal single-lung ventilation/intense pleural infl → Convert to OT

WHEN NOT TO DO?

# CONTRA-INDICATIONS

- Uncommon , rarely absolute
1. Size of free pl space <6-10 cm usually due to extensive adhesions
  2. Others:
    - Intractable cough
    - Hypoxemia
    - Bleeding and coagulation disorders
    - Unstable cardiovascular status
    - Contraindications for GA (for VATS)

# CONTRA-INDICATIONS

- Pul Bx avoided if:
  1. MPAP > 35 mm Hg
  2. End stage pul fibrosis with extensive honeycombing
  3. Suspicion of PAVM, hydatid cyst or vascular tumours

WHY NOT TO DO?



# COMPLICATIONS

## *MT:*

- Mortality 0.01-0.25 %
- Morbidity:
  - Transient hyperthermia (<38.5 C) x 12-24 hrs - 15 %
  - Desaturation during procedure (↓ LA) - <2%
  - Persistent post op air leak (>7 d) - <2% (pts with spontaneous pneumothorax) → likely disease related
  - S/C emphysema ~ 0.5%
  - Negligible - benign cardiac arrhythmias, transient hypotension and seeding of path in pts with MM

# COMPLICATIONS

## VATS:

- Mortality <1 % (~0.3 %)
- Morbidity:
  - Anesthesia Related OR Instrument Related OR Procedure Related
  - Conversion to OT ≈1–5% (Adhesions, equipment failure, uncontrolled bleeding)
  - Persistent post op air leak (>7 d) ~4%
  - Post op bleeding req intervention ~ 0.5–1.5%

HOW TO DO?

# PROCEDURE


## *Single Puncture:*

- Rigid thoracoscope (W.C.=3–5 mm), Trocar (Obturator + Sheath/Cannula = 10 mm dia)

## *Double Puncture:*

- Trocars:
  - Obturator (D = 7 mm & L = 10 cm – 1<sup>st</sup> entry point)
  - Obturator (D = 5 mm & L = 10 cm – 2<sup>nd</sup> entry point)
- Telescope: Direct/oblique visions  $\approx 180^\circ/50^\circ$
- Forceps:
  - 7 mm optical forceps (1<sup>st</sup> point of entry)
  - 5 mm coagulating forceps (2<sup>nd</sup> point of entry) – useful for Bx of thick hard fibrous pl lesions (esp plaques) & visceral pl + lung


# PROCEDURE




**Trocar + Cannula with Valve**



**Single Incision Thoracoscope**



**Bx Forceps with Straight optics**



**Optics & Forceps in Shaft**



# PROCEDURE

## *Points of Entry:*


- First Point:
  - 3<sup>rd</sup>-4<sup>th</sup> ICS Axilla (SP → UL)
  - 6<sup>th</sup>-7<sup>th</sup> ICS Axilla (PE → Diaphragm/Costovertebral gutters)
  - 4<sup>th</sup>-5<sup>th</sup> ICS Axilla (Lung Bx → all lobes)
- Second Point:
  - Determined after visualization by a oblique viewing 50° telescope

# PROCEDURE

**3 STICK APPROACH**




# PROCEDURE





# PROCEDURE



# PROCEDURE

## *Induction of Pneumothorax:*

- Req'd for introduction of scope into pl cavity – enough space to move all instruments around easily & visualize all important areas
- Pl trocar 2-3 mm dia/100 mm length – Pointed obturator (skin, I/C muscles) & blunt (parietal pl)
- Ordinary needles sharp → risk of lung puncture
- Oscillations on manometer → large & -ve (-8 to -2 cm H<sub>2</sub>O) – lung puncture (low ampl, ≈0)

# PROCEDURE

## *Chest Drain:*

- ICTD inserted at end of procedure
- Removed:
  - After 3-4 hrs – as soon as lung re-expanded (normal Dx procedure)
  - After 24-48 hrs (Lung Bx)
  - After 2-5 days when fluid output ↓ (Pleurodesis)

WHAT NEXT ?

# FUTURE DIRECTIONS

## *Mediastinal Disease:*

- Post & middle mediastinal tumors → convert to OT > 10% (poor access)
- Evaluation of hilar/ant mediastinal LNE (not accessible to PCNA, TBNA or TENA) → alt to cervical mediastinoscopy & ant mediastinotomy
- Resection of bronchogenic cysts
- Utility of VATS analyzed in 34 pts with mediastinal disease (LN, thymic, cystic & solid lesions) → Useful for small lesions

*Kitami et al Ann Thorac Cardiovasc Surg.*

# FUTURE DIRECTIONS

## *Vasospastic Disease:*

- Sympathectomies indicated in Raynaud's syndrome, causalgia or essential hyperhydrosis
- Thoracoscopic UL sympathectomy safe, effective

*Satyapal et al Clin Anat. 2003; 16: 538-41.*

- Ablation of sympathetic ganglia by phenol injection, electrocoagulation or laser photocoagulation
- Done thru axillary/ant approach

# FUTURE DIRECTIONS

## *CVS Diseases*

1. Ligation of PDA
2. Harvest IMA in pts undergoing CABG
3. Drainage of pericardial effusions esp malignant
  - Significant reduction in postop pain

# FUTURE DIRECTIONS

## *USG guided MT*

- TT USG to locate safe entry site for trocar placement for MT without induction of a preprocedure pneumothorax
- USG could safely, reliably & successfully identify entry sites in all 20 pts (even in presence of pl adhesions)

*Hersh CP et al. Respiration 2003; 70:299-*

*301*

- USG Replacing practice of pneumothorax induction before MT?




# FUTURE DIRECTIONS

## *Minithoracoscopy*


- Smaller instruments used (3-mm)
  - Usually 2 ports of entry
  - 17 small loculated PE (not accessible with standard-sized MT) & 12 larger nonloculated effusions (could have been examined using conventional MT) → Diagnostic yield = 93.4%
- Visualization equal to conventional MT

*Tassi et al Chest. 2003; 124: 1975-1977.*


**DIAGNOSIS**




**TREATMENT**



DIAGNOSIS



TREATMENT



# CONCLUSIONS

- MT & VATS useful for Dx & Rx of variety of pleural and even pulmonary/mediastinal diseases
- MT (~ VATS) – adv of being done ↓ LA, in an endoscopy procedure room, using nondisposable instruments (Safer, less invasive & less expensive)
- Whenever available MT & VATS should be used for Mx of pleuropulmonary diseases